# Shanghai Allist Pharmaceuticals

Source: https://onco.cc/companies/allist/  
OnCo record `allist` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Allist is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR pill, partnered with ArriVent for the rest of the world.

## Summary

Shanghai Allist Pharmaceuticals, based in Shanghai, founded in 2004 and listed as 688578.SS, is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR tablet, partnered with ArriVent for the rest of the world. Furmonertinib, sold as Ivesa, was approved in 2021 and for first-line use in 2022 on the FURLONG trial, and its exon 20 insertion programme is licensed to ArriVent BioPharma in the United States with the global FURVENT phase 3. OnCo links it to furmonertinib and FURLONG. Its profitability on one drug shows the size of China's EGFR-mutant lung cancer market, and whether the exon 20 programme gives it a global product rather than a domestic one is the open question. Furmonertinib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: Allist; 艾力斯
- Tags: china
- HQ: Shanghai
- Type: biotech
- Website: https://www.allist.com.cn/
- Ticker: 688578.SS

## Sources

- Official website: https://www.allist.com.cn/

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [Sitneprotafib](https://onco.cc/drugs/sitneprotafib/)
- trials: [A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.](https://onco.cc/trials/nct06008288/), [A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases](https://onco.cc/trials/nct06970639/), [A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China](https://onco.cc/trials/nct05009329/), [A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1](https://onco.cc/trials/nct05276726/), [Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion](https://onco.cc/trials/nct05466149/), [Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation](https://onco.cc/trials/nct06956001/), [FURLONG](https://onco.cc/trials/furlong/), [Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA](https://onco.cc/trials/nct05334277/), [JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation](https://onco.cc/trials/nct06416410/), [JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation](https://onco.cc/trials/nct05194995/), [Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation](https://onco.cc/trials/nct05288205/), [To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy](https://onco.cc/trials/nct04853342/)

---
JSON: https://onco.cc/api/v1/entities/allist.json